No Data
No Data
Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Cuts Target Price to $18
Stoke Therapeutics Assumed With an Outperform at Leerink
Stoke Therapeutics Files Mixed Shelf
Express News | Stoke Therapeutics Inc - Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely